← Back to Search

Electrolyte Supplement

Magnesium for Cardiac Arrest

Phase 1
Waitlist Available
Led By Sam Parnia
Research Sponsored by NYU Langone Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Must not have
Age < 18 years or > 85 years
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 90
Awards & highlights

Summary

This trial aims to see if giving magnesium sulfate to patients after they have been resuscitated from a cardiac arrest can protect their brain. The study will look at the safety and feasibility of giving magnesium and

Who is the study for?
This trial is for patients who have had a cardiac arrest and were successfully resuscitated (ROSC). It's a preliminary study, so the main goal is to see if it's feasible and safe to give magnesium sulfate as brain protection after the event. Details on specific inclusion or exclusion criteria are not provided.
What is being tested?
The study tests whether giving magnesium sulfate can protect the brain after someone has been brought back from cardiac arrest. Patients will be compared with those receiving saline, which is a standard treatment without active medication.
What are the potential side effects?
Possible side effects of magnesium sulfate may include low blood pressure, flushing, drowsiness, muscle weakness, respiratory depression or heart rate changes. Saline typically has fewer side effects but may cause vein irritation.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am between 18 and 85 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 90
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 90 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Proportion of cases for which serum is successfully drawn and analyzed
Proportion of cases where Magnesium (Mg) or saline bolus was delivered with a goal of <2 h after return of spontaneous circulation (ROSC)
Proportion of cases where patient's CPC status is assessed
+3 more
Secondary outcome measures
All-cause mortality
Number of participants with adverse reactions related to magnesium therapy
Proportion of cases for which magnesium levels are found to be 8.1-10 mg/dl
+3 more

Side effects data

From 2012 Phase 4 trial • 200 Patients • NCT01342510
30%
Pain with injection of propofol
100%
80%
60%
40%
20%
0%
Study treatment Arm
Lidocaine/Magnesium
Control
Lidocaine
Magnesium

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Magnesium SulfateExperimental Treatment1 Intervention
Treatment of initial magnesium sulfate bolus followed by a continuous drip.
Group II: Saline solutionPlacebo Group1 Intervention
Treatment of equivalent volume of normal saline.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Magnesium Sulfate
2011
Completed Phase 4
~5160

Find a Location

Who is running the clinical trial?

NYU Langone HealthLead Sponsor
1,379 Previous Clinical Trials
847,940 Total Patients Enrolled
2 Trials studying Cardiac Arrest
823 Patients Enrolled for Cardiac Arrest
National Heart, Lung, and Blood Institute (NHLBI)NIH
3,854 Previous Clinical Trials
47,817,694 Total Patients Enrolled
14 Trials studying Cardiac Arrest
30,020 Patients Enrolled for Cardiac Arrest
Sam ParniaPrincipal InvestigatorNYU Langone Health
~119 spots leftby Apr 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top